KGEL Vaccine After Initial Therapy of Hodgkin's Lymphoma
OBJECTIVES:
- Determine immunologic responses in patients who have completed first-line therapy for
Hodgkin's lymphoma treated with Hodgkin's antigens-GM-CSF-expressing cell vaccine.
- Determine the durability of these immunologic responses in these patients.
- Determine the utility of an Epstein-Barr virus reporter system for monitoring cellular
vaccine responses.
- Determine the safety and tolerability of this vaccine in these patients.
OUTLINE: Beginning 4-6 months after last chemotherapy, patients receive Hodgkin's
antigens-GM-CSF-expressing cell vaccine on day 1. Treatment repeats every 3 weeks for up to
4 courses.
Immunologic responses are serially monitored along with disease status.
PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study.
Interventional
Masking: Open Label, Primary Purpose: Treatment
Immunologic response
No
Yvette L. Kasamon, MD
Study Chair
Sidney Kimmel Comprehensive Cancer Center
United States: Federal Government
J06143 CDR0000544408
NCT00478062
April 2007
June 2008
Name | Location |
---|---|
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore, Maryland 21231-2410 |